Symbols / ANL Stock $15.50 +8.62% Adlai Nortye Ltd.

Healthcare • Biotechnology • United States • NGM
ANL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Yang Lu
Exch · Country NGM · United States
Market Cap 998.17M
Enterprise Value 1.88B
Income -35.53M
Sales 5.00M
FCF (ttm) -37.69M
Book/sh -0.21
Cash/sh 0.07
Employees 109
Insider 10d —
IPO Sep 29, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -44.93
PEG —
P/S 199.63
P/B -74.52
P/C —
EV/EBITDA -53.74
EV/Sales 375.49
Quick Ratio 0.22
Current Ratio 0.65
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.11
EPS next Y -0.34
EPS Growth —
Revenue Growth 178.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -42.22%
ROE -4.14%
ROIC —
Gross Margin 100.00%
Oper. Margin -3.30%
Profit Margin 0.00%
Shs Outstand 58.73M
Shs Float 66.38M
Insider Own 5.66%
Instit Own 6.90%
Short Float 4.89%
Short Ratio 5.32
Short Interest 2.29M
52W High 17.25
vs 52W High -10.14%
52W Low 0.88
vs 52W Low 1,663.37%
Beta -0.71
Impl. Vol. —
Rel Volume 1.43
Avg Volume 409.53K
Volume 587.67K
Target (mean) $29.67
Tgt Median $23.00
Tgt Low $20.00
Tgt High $46.00
# Analysts 3
Recom Strong_buy
Prev Close $14.27
Price $15.50
Change 8.62%
About

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.67
Mean price target
2. Current target
$15.50
Latest analyst target
3. DCF / Fair value
$-11.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.50
Low
$20.00
High
$46.00
Mean
$29.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 main HC Wainwright & Co. Buy → Buy $20
2026-02-13 up HC Wainwright & Co. Neutral → Buy $16
2025-06-02 down HC Wainwright & Co. Buy → Neutral —
2024-11-11 reit HC Wainwright & Co. Buy → Buy $9
2024-10-18 reit HC Wainwright & Co. Buy → Buy $9
2024-09-04 init HC Wainwright & Co. — → Buy $9
2024-06-20 reit Cantor Fitzgerald — → Overweight —
2023-10-24 init Cantor Fitzgerald — → Overweight $30
News
RSS: Latest ANL news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
5.00
0.00
0.00
0.00
Operating Revenue
5.00
0.00
0.00
0.00
Operating Expense
40.70
-23.11%
52.93
-27.05%
72.55
+7.85%
67.27
Research And Development
32.83
-26.90%
44.91
-22.76%
58.15
+6.72%
54.49
Selling General And Administration
7.79
-17.56%
9.44
-36.30%
14.82
+19.26%
12.43
General And Administrative Expense
7.79
-17.56%
9.44
-36.30%
14.82
+19.26%
12.43
Salaries And Wages
4.81
-19.79%
5.99
-2.90%
6.17
-24.72%
8.20
Other Gand A
2.98
-13.69%
3.45
-60.13%
8.65
+104.52%
4.23
Other Operating Expenses
-0.40
+79.59%
-1.94
-117.98%
-0.89
-243.63%
-0.26
Total Expenses
40.70
-23.11%
52.93
-27.05%
72.55
+7.85%
67.27
Operating Income
-35.70
+32.55%
-52.93
+27.05%
-72.55
-7.85%
-67.27
Total Operating Income As Reported
-35.70
+32.55%
-52.93
+27.05%
-72.55
-7.85%
-67.27
EBITDA
-32.63
+32.10%
-48.05
+54.76%
-106.22
-88.61%
-56.32
Normalized EBITDA
-32.63
+32.10%
-48.05
+54.78%
-106.28
-85.31%
-57.35
Reconciled Depreciation
1.41
-24.44%
1.87
-15.84%
2.22
+8.87%
2.04
EBIT
-34.04
+31.82%
-49.92
+53.96%
-108.44
-85.82%
-58.36
Total Unusual Items
0.00
—
0.06
-94.00%
1.03
Total Unusual Items Excluding Goodwill
0.00
—
0.06
-94.00%
1.03
Net Income
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Pretax Income
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Net Non Operating Interest Income Expense
-1.53
+21.24%
-1.94
-145.76%
-0.79
-82.68%
-0.43
Interest Expense Non Operating
1.49
-23.46%
1.94
+145.76%
0.79
+82.68%
0.43
Net Interest Income
-1.53
+21.24%
-1.94
-145.76%
-0.79
-82.68%
-0.43
Interest Expense
1.49
-23.46%
1.94
+145.76%
0.79
+82.68%
0.43
Interest Income Non Operating
—
—
0.06
-88.73%
0.55
Interest Income
—
—
0.06
-88.73%
0.55
Other Income Expense
1.70
-43.36%
3.00
+108.37%
-35.89
-502.63%
8.91
Other Non Operating Income Expenses
1.70
-43.37%
3.01
+108.36%
-35.95
-556.25%
7.88
Gain On Sale Of Security
0.00
—
0.06
-94.00%
1.03
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Net Income From Continuing Operation Net Minority Interest
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Net Income From Continuing And Discontinued Operation
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Net Income Continuous Operations
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Normalized Income
-35.53
+31.50%
-51.87
+52.54%
-109.29
-82.69%
-59.82
Net Income Common Stockholders
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Diluted EPS
-1.11
+31.48%
-1.62
+78.57%
-7.56
-374.51%
-1.59
Basic EPS
-1.11
+31.48%
-1.62
+78.57%
-7.56
-374.51%
-1.59
Basic Average Shares
31.97
+0.15%
31.93
+120.98%
14.45
-60.85%
36.90
Diluted Average Shares
31.97
+0.15%
31.93
+120.98%
14.45
-60.85%
36.90
Diluted NI Availto Com Stockholders
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Depreciation Amortization Depletion Income Statement
0.48
-6.67%
0.51
+9.68%
0.47
-23.65%
0.61
Depreciation And Amortization In Income Statement
0.48
-6.67%
0.51
+9.68%
0.47
-23.65%
0.61
Earnings From Equity Interest
-0.00
+25.00%
-0.00
0.00
0.00
Total Other Finance Cost
0.04
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
34.43
-51.69%
71.27
-45.26%
130.19
+79.34%
72.59
Current Assets
26.89
-58.02%
64.06
-36.69%
101.19
+52.63%
66.30
Cash Cash Equivalents And Short Term Investments
8.06
-86.77%
60.91
-38.16%
98.50
+53.80%
64.05
Cash And Cash Equivalents
8.06
-86.77%
60.90
-33.43%
91.49
+113.98%
42.76
Cash Financial
8.06
-86.77%
60.90
-33.43%
91.49
—
Other Short Term Investments
0.00
-100.00%
0.01
-99.90%
7.01
-67.08%
21.29
Receivables
1.39
+18.40%
1.17
+227.02%
0.36
+3.76%
0.35
Other Receivables
0.91
+262.80%
0.25
+11.61%
0.22
-8.94%
0.25
Taxes Receivable
0.47
-48.57%
0.91
+574.07%
0.14
+35.00%
0.10
Prepaid Assets
1.72
-13.38%
1.98
-15.23%
2.34
+22.23%
1.91
Restricted Cash
15.73
0.00
—
—
Total Non Current Assets
7.54
+4.65%
7.21
-75.15%
28.99
+360.88%
6.29
Net PPE
3.02
+11.65%
2.71
-28.82%
3.80
-35.32%
5.88
Gross PPE
7.47
+17.83%
6.34
-18.10%
7.74
-11.04%
8.71
Accumulated Depreciation
-4.45
-22.44%
-3.64
+7.78%
-3.94
-39.36%
-2.83
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
1.80
+88.59%
0.95
-15.64%
1.13
-45.73%
2.09
Machinery Furniture Equipment
2.94
+1.90%
2.89
-25.25%
3.87
+1.42%
3.81
Other Properties
0.26
+1.95%
0.26
+12.72%
0.23
-17.39%
0.28
Leases
2.47
+10.04%
2.24
-11.04%
2.52
-0.51%
2.53
Goodwill And Other Intangible Assets
0.02
-52.50%
0.04
-36.51%
0.06
-29.21%
0.09
Other Intangible Assets
0.02
-52.50%
0.04
-36.51%
0.06
-29.21%
0.09
Investments And Advances
4.25
+2.21%
4.16
-83.27%
24.85
0.00
Long Term Equity Investment
4.25
+2.21%
4.16
0.00
—
Non Current Accounts Receivable
—
—
—
—
Non Current Prepaid Assets
—
0.30
0.00
0.00
Other Non Current Assets
0.25
-16.78%
0.30
+7.80%
0.28
-13.76%
0.33
Total Liabilities Net Minority Interest
42.76
-6.62%
45.78
-16.97%
55.14
-82.43%
313.89
Current Liabilities
41.63
-8.23%
45.36
-8.68%
49.67
-84.11%
312.65
Payables And Accrued Expenses
16.38
+20.80%
13.56
-27.08%
18.59
+9.54%
16.98
Payables
13.23
+26.10%
10.50
-28.99%
14.78
+10.69%
13.35
Accounts Payable
12.64
+24.56%
10.15
-29.29%
14.35
+9.54%
13.10
Other Payable
0.58
+110.55%
0.28
-9.24%
0.30
+18.82%
0.26
Current Accrued Expenses
3.14
+2.64%
3.06
-19.69%
3.81
+5.30%
3.62
Total Tax Payable
0.02
-76.00%
0.07
-42.31%
0.13
—
Current Debt And Capital Lease Obligation
25.25
-5.79%
26.80
-13.76%
31.08
+485.51%
5.31
Current Debt
24.58
-6.64%
26.33
-13.27%
30.36
+604.83%
4.31
Current Capital Lease Obligation
0.67
+41.61%
0.47
-34.76%
0.72
-27.87%
1.00
Current Deferred Liabilities
0.00
-100.00%
5.00
0.00
—
Current Deferred Revenue
0.00
-100.00%
5.00
0.00
—
Other Current Liabilities
—
—
—
290.37
Total Non Current Liabilities Net Minority Interest
1.13
+165.18%
0.42
-92.23%
5.47
+342.48%
1.24
Long Term Debt And Capital Lease Obligation
1.13
+165.18%
0.42
-9.38%
0.47
-62.06%
1.24
Long Term Capital Lease Obligation
1.13
+165.18%
0.42
-9.38%
0.47
-62.06%
1.24
Non Current Deferred Liabilities
—
0.00
-100.00%
5.00
—
Non Current Deferred Revenue
—
0.00
-100.00%
5.00
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
-8.32
-132.65%
25.48
-66.04%
75.05
+131.10%
-241.29
Common Stock Equity
-8.32
-132.65%
25.48
-66.04%
75.05
+129.75%
-252.27
Capital Stock
0.01
+9.09%
0.01
+0.00%
0.01
-99.90%
10.98
Common Stock
0.01
+9.09%
0.01
+0.00%
0.01
+175.00%
0.00
Preferred Stock
—
0.00
0.00
-100.00%
10.98
Share Issued
176.22
+59.19%
110.70
0.00%
110.70
+0.00%
110.70
Ordinary Shares Number
176.22
+59.19%
110.70
0.00%
110.70
+0.00%
110.70
Additional Paid In Capital
439.27
+0.06%
439.02
+0.07%
438.71
+6738.77%
6.42
Retained Earnings
-464.85
-8.28%
-429.32
-13.74%
-377.45
-40.72%
-268.22
Gains Losses Not Affecting Retained Earnings
-4.35
+4.17%
-4.54
-6.93%
-4.24
-1.97%
-4.16
Total Equity Gross Minority Interest
-8.32
-132.65%
25.48
-66.04%
75.05
+131.10%
-241.29
Total Capitalization
-8.32
-132.65%
25.48
-66.04%
75.05
+131.10%
-241.29
Working Capital
-14.74
-178.79%
18.70
-63.70%
51.52
+120.91%
-246.35
Invested Capital
16.26
-68.62%
51.81
-50.84%
105.40
+142.51%
-247.97
Total Debt
26.38
-3.12%
27.23
-13.70%
31.55
+382.09%
6.54
Net Debt
16.53
—
—
—
Capital Lease Obligations
1.79
+100.22%
0.90
-24.77%
1.19
-46.76%
2.24
Net Tangible Assets
-8.34
-132.78%
25.45
-66.07%
74.98
+131.06%
-241.38
Tangible Book Value
-8.34
-132.78%
25.45
-66.07%
74.98
+129.71%
-252.36
Available For Sale Securities
—
—
24.85
—
Derivative Product Liabilities
—
—
—
—
Duefrom Related Parties Current
0.01
+7.14%
0.01
0.00
—
Foreign Currency Translation Adjustments
-4.35
+4.17%
-4.54
-6.93%
-4.24
-1.97%
-4.16
Investmentin Financial Assets
—
0.00
-100.00%
24.85
0.00
Line Of Credit
24.58
-6.64%
26.33
-13.27%
30.36
+604.83%
4.31
Other Equity Interest
21.59
+6.31%
20.31
+12.73%
18.02
+31.63%
13.69
Preferred Stock Equity
—
—
—
10.98
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-33.45
+35.44%
-51.82
+8.53%
-56.65
-31.07%
-43.22
Cash Flow From Continuing Operating Activities
-33.45
+35.44%
-51.82
+8.53%
-56.65
-31.07%
-43.22
Net Income From Continuing Operations
-35.53
+31.50%
-51.87
+52.51%
-109.23
-85.79%
-58.79
Depreciation Amortization Depletion
1.41
-24.44%
1.87
-15.84%
2.22
+8.87%
2.04
Depreciation
1.39
-24.73%
1.85
-15.89%
2.20
+8.71%
2.02
Amortization Cash Flow
0.02
+0.00%
0.02
-12.00%
0.03
+25.00%
0.02
Depreciation And Amortization
1.41
-24.44%
1.87
-15.84%
2.22
+8.87%
2.04
Amortization Of Intangibles
0.02
+0.00%
0.02
-12.00%
0.03
+25.00%
0.02
Other Non Cash Items
1.42
+13.84%
1.24
+57.14%
0.79
+82.68%
0.43
Stock Based Compensation
1.53
-37.47%
2.45
-43.42%
4.33
-28.81%
6.08
Operating Gains Losses
0.00
-92.59%
0.03
+143.55%
-0.06
+88.87%
-0.56
Gain Loss On Investment Securities
-0.00
—
-0.06
+88.73%
-0.55
Unrealized Gain Loss On Investment Securities
0.00
0.00
-100.00%
39.17
+610.11%
-7.68
Gain Loss On Sale Of PPE
0.00
-100.00%
0.02
0.00
+100.00%
-0.01
Change In Working Capital
-2.29
+58.74%
-5.54
-190.46%
6.12
-59.83%
15.25
Change In Prepaid Assets
0.17
+135.87%
-0.46
-5.50%
-0.44
-110.03%
4.35
Change In Payables And Accrued Expense
2.50
+149.39%
-5.06
-433.86%
1.51
-85.94%
10.77
Change In Payable
2.50
+149.39%
-5.06
-433.86%
1.51
-85.94%
10.77
Change In Account Payable
2.49
+159.28%
-4.20
-435.62%
1.25
-87.62%
10.12
Change In Other Working Capital
-5.00
—
5.00
—
Change In Other Current Assets
0.05
+331.82%
-0.02
-148.89%
0.04
-64.84%
0.13
Investing Cash Flow
-15.58
-155.51%
28.07
+356.21%
-10.95
-138.60%
28.38
Cash Flow From Continuing Investing Activities
-15.58
-155.51%
28.07
+356.21%
-10.95
-138.60%
28.38
Net PPE Purchase And Sale
-0.19
-36.50%
-0.14
+31.16%
-0.20
+83.85%
-1.23
Purchase Of PPE
-0.19
-10.00%
-0.17
+15.00%
-0.20
+83.99%
-1.25
Sale Of PPE
0.00
-100.00%
0.03
+3200.00%
0.00
-94.12%
0.02
Capital Expenditure
-0.19
-10.00%
-0.17
+15.00%
-0.20
+84.23%
-1.27
Net Investment Purchase And Sale
-15.39
-148.54%
31.71
+393.18%
-10.82
-137.20%
29.08
Purchase Of Investment
-20.43
+66.25%
-60.55
-90.06%
-31.86
+45.99%
-58.98
Sale Of Investment
5.04
-94.54%
92.26
+338.51%
21.04
-76.11%
88.06
Net Business Purchase And Sale
0.00
+100.00%
-4.21
0.00
0.00
Purchase Of Business
0.00
+100.00%
-4.21
0.00
0.00
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-0.02
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-0.02
Net Other Investing Changes
—
—
—
0.55
Financing Cash Flow
-3.81
+42.06%
-6.58
-105.66%
116.24
+1814.45%
-6.78
Cash Flow From Continuing Financing Activities
-3.81
+42.06%
-6.58
-105.66%
116.24
+1814.45%
-6.78
Net Issuance Payments Of Debt
-2.64
+45.62%
-4.86
-119.39%
25.06
+486.28%
-6.49
Issuance Of Debt
37.72
-15.62%
44.70
-11.01%
50.23
+536.11%
7.90
Repayment Of Debt
-40.36
+18.56%
-49.56
-96.89%
-25.17
-74.99%
-14.38
Long Term Debt Payments
-0.63
+37.94%
-1.02
+7.52%
-1.10
-3.08%
-1.07
Net Long Term Debt Issuance
-0.63
+37.94%
-1.02
+7.52%
-1.10
-3.08%
-1.07
Short Term Debt Issuance
37.72
-15.62%
44.70
-11.01%
50.23
+536.11%
7.90
Short Term Debt Payments
-39.73
+18.16%
-48.54
-101.68%
-24.07
-80.77%
-13.31
Net Short Term Debt Issuance
-2.01
+47.66%
-3.84
-114.68%
26.16
+582.93%
-5.42
Net Common Stock Issuance
0.00
0.00
-100.00%
91.78
0.00
Cash Dividends Paid
0.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.15
0.00
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
-52.84
-74.21%
-30.33
-162.37%
48.63
+324.88%
-21.63
Effect Of Exchange Rate Changes
-0.00
+98.83%
-0.26
-357.00%
0.10
-60.63%
0.25
Beginning Cash Position
60.90
-33.43%
91.49
+113.98%
42.76
-33.33%
64.13
End Cash Position
8.06
-86.77%
60.90
-33.43%
91.49
+113.98%
42.76
Free Cash Flow
-33.64
+35.30%
-51.99
+8.55%
-56.85
-27.78%
-44.49
Common Stock Issuance
0.00
0.00
-100.00%
91.78
0.00
Earnings Losses From Equity Investments
0.00
-25.00%
0.00
0.00
0.00
Interest Paid CFF
-1.17
+37.52%
-1.87
-210.80%
-0.60
-106.16%
-0.29
Interest Paid CFO
—
0.00
+100.00%
-0.06
+88.73%
-0.55
Interest Received CFI
0.00
-99.86%
0.70
+1030.65%
0.06
-88.73%
0.55
Interest Received CFO
—
0.00
+100.00%
-0.06
+88.73%
-0.55
Issuance Of Capital Stock
0.00
0.00
-100.00%
91.78
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category